Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | CASR | P41180 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9568576 | 0.82 | HTT (0.38) | HTTSNCAALDH1A1HSD17B10CASR | |
| SCHEMBL9615906 | 0.81 | HTT (0.43) | HTTSNCAALDH1A1HSD17B10LMNA | |
| SCHEMBL600325 | 0.79 | ALDH1A1 (0.36) | HTTSNCAALDH1A1HSD17B10CASR | |
| SCHEMBL644415 | 0.77 | CYP1A2 (0.36) | HTTSNCAALDH1A1HSD17B10LMNA | |
| SCHEMBL9568601 | 0.77 | NR1I2 (0.35) | HTTSNCAALDH1A1HSD17B10LMNA | |
| SCHEMBL9101581 | 0.76 | HTT (0.43) | HTTSNCAALDH1A1HSD17B10LMNA | |
| SCHEMBL17417188 | 0.76 | HTT (0.54) | HTTSNCAALDH1A1HSD17B10LMNA | |
| SCHEMBL9542136 | 0.76 | CA2 (0.36) | HTTSNCAALDH1A1HSD17B10LMNA | |
| SCHEMBL10954377 | 0.76 | HTT (0.34) | HTTSNCAALDH1A1HSD17B10CASR | |
| SCHEMBL28564255 | 0.76 | LMNA (0.42) | HTTSNCAALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4051662-B1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL}METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-07 | — | — | EP | disclosed |
| WO-2021083998-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-06 | — | — | WO | disclosed |
| EP-3092240-B1 | ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2018-12-05 | — | — | EP | disclosed |
| US-9809592-B2 | Isopropyl triazolo pyridine compounds | ELI LILLY AND COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160333005-A1 | ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-11-17 | — | — | US | disclosed |
| CN-105246875-A | Indane derivative, preparation method therefor, and pharmaceutical application thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-01-13 | — | — | CN | disclosed |
| WO-2015032328-A1 | INDANE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 (CN) | 2015-03-12 | — | — | WO | disclosed |
| EP-2470546-B1 | HEXAHYDROOXAZINOPTERIDINE COMPOUNDS FOR USE AS MTOR INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8268819-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2470546-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8163755-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2011025889-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333005-A1 | ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS | INSR, INSRR, GPR119 | HTT 3609/4885SNCA 4177/4885ALDH1A1 2406/4885 |
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | HPRT1, HCCS, NUDT1 | HTT 880/4885SNCA 4002/4885ALDH1A1 2074/4885 |
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | HTR3C, MECP2, CDK2 | HTT 2786/4885SNCA 1781/4885ALDH1A1 1540/4885 |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | MTOR, RICTOR, EIF4EBP1 | HTT 174/4885SNCA 4658/4885ALDH1A1 4123/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | HTT 3209/4885SNCA 4838/4885ALDH1A1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.